2 pharma stocks that could make you a millionaire

The FTSE 100 isn’t the last word for great pharmaceutical stocks. Here, Royston Wild looks at two medical marvels outside of the blue-chip index.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

While GlaxoSmithKline and AstraZeneca may be the first port of call for many investors looking to get a foothold in the pharmaceuticals sector, they are by no means the only hot stocks expected to deliver blockbuster earnings expansion in the years ahead.

Indeed, there are a broad range of medicine producers tipped to produce brilliant returns this year and beyond. And in this article I am looking at two of these pharma fizzers: BTG (LSE: BTG) and Dechra Pharmaceuticals (LSE: DPH).

The right treatment

BTG’s latest trading statement this month reinforced my optimistic take further, the company noting that “there is good momentum across the business with significant progress achieved during the [half-year] period.”

The business saw product sales at constant currencies rise by double-digit percentages during April-September, meaning that full-year sales targets remain in sight. Revenues at its Specialty Pharmaceuticals division are expected to swell by low-to-mid single digits at stable exchange rates, BTG advised, while sales at Interventional Medicine should rise in the mid-to-high teens.

This was not the only positive news BTG furnished the market with last week. Indeed, the company announced that its aggressive M&A drive has seen it acquire US-based Roxwood Medical — which provides cardiovascular speciality catheters for use in patients with heart trouble — for a fee which could eventually rise to $80m. Revenues at Roxwood should balloon in the years ahead and provide synergetic benefits to BTG’s existing operations in this area.

BTG has seen earnings rattle steadily higher in recent years, and City brokers are expecting meaty growth of 27% in the year ending March 2018. An additional 14% advance is pencilled in for fiscal 2019 too.

And these projections make the FTSE 250 star excellent value too. Sure, a forward P/E ratio of 24.1 times may sit well outside the widely-considered value watermark of 15 times. However, a corresponding PEG reading of 0.9 suggests BTG is actually brilliantly priced relative to its growth potential.

Animal spirits

Animalcare specialist Dechra Pharmaceuticals (LSE: DPH) is another pharma share expected to deliver stonking profits growth in the nearterm and beyond.

Like BTG, the Cheshire-based entity has a long history of annual earnings rises behind it. And City analysts are not expecting this impressive run to end just yet, a chunky 13% rise being forecast for the 12 months ending June 2018.

Dechra has also been hot on the M&A trail in recent years to bolster its already impressive product pipeline and expand its geographical footprint, a strategy which keeps blasting revenues skywards (at constant currencies sales increased 28.3% during the 12 months to June, to £359.3m).

Rampant share picker demand has seen Dechra’s share price head for the clouds in recent months, the business gaining 60% in value since the turn of 2017. While this also leaves the business dealing on a conventionally-high forward P/E ratio of 29.4 times, I believe this is fair value given that medicines demand for domestic and agricultural animals should continue climbing at a stratospheric rate.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca and BTG. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »